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Background: Usher syndrome (USH) is an autosomal recessive genetically heterogeneous disorder with congenital
sensorineural hearing impairment and retinitis pigmentosa (RP). We have identified a consanguineous Lebanese
family with two affected members displaying progressive hearing loss, RP and cataracts, therefore clinically
diagnosed as USH type 3 (USH3). Our study was aimed at the identification of the causative mutation in this USH3-
like family.
Methods: Candidate loci were identified using genomewide SNP-array-based homozygosity mapping followed by
targeted enrichment and next-generation sequencing.
Results: Using a capture array targeting the three identified homozygosity-by-descent regions on chromosomes
1q43-q44, 20p13-p12.2 and 20p11.23-q12, we identified a homozygous nonsense mutation, p.Arg65X, in ABHD12
segregating with the phenotype.
Conclusion: Mutations of ABHD12, an enzyme hydrolyzing an endocannabinoid lipid transmitter, cause PHARC
(polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, and early-onset cataract). After the identification of the
ABHD12 mutation in this family, one patient underwent neurological examination which revealed ataxia, but no
polyneuropathy. ABHD12 is not known to be related to the USH protein interactome. The phenotype of our patient
represents a variant of PHARC, an entity that should be taken into account as differential diagnosis for USH3. Our
study demonstrates the potential of comprehensive genetic analysis for improving the clinical diagnosis.
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Usher syndrome (USH) is an autosomal recessive dis-
order manifesting in about 10% of children with con-
genital sensorineural hearing impairment, characterized
by additional retinitis pigmentosa (RP). The clinical sub-
type USH1 presents with severe to profound hearing
loss, vestibular impairment and early RP, whereas USH2
is characterized by moderate to severe hearing impairment* Correspondence: hanno.bolz@bioscientia.de
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distribution, and reproduction in any mediumand RP in adolescence. USH3 is very rare and variable; it
may resemble USH1 or USH2, and vestibular dysfunction
may be present. Ten genes (including a digenic contribu-
tor and modifier, PDZD7) have been implicated in USH
[1-3]. Clarin-1 (CLRN1) has been the only known USH3
gene to date (locus: USH3A) until recently, when HARS,
encoding histidyl-tRNA synthetase, has been proposed as
a novel USH3 gene [4]. Moreover, Dad et al. have mapped
a condition with clinical overlap to USH3 (RP, progressive
hearing impairment, vestibular dysfunction, and congeni-
tal cataract) to chromosome 15q22.2-23 [5].ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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with an USH3-like phenotype. The patients exhibited
sensorineural hearing loss, RP and cataracts, an ocular
complication USH patients are predisposed for. Our
study aimed at identifying the causative mutation – and
potentially the second USH3 gene – in this family by
homozygosity mapping and targeted next-generation
sequencing (NGS). After the identification of a homozy-
gous truncating mutation in a known disease gene,
ABHD12, one patient was re-examined and found to dis-
play ataxia, reversing the diagnosis to a neurodegenerative
disease, PHARC, that is characterized by polyneuropathy,




The study was approved by the institutional review
board (IRB) at the American University of Beirut andFigure 1 PHARC family described herein and conducted genetic inves
of the LOD score calculation of genomewide SNP mapping. Regions show
20 (two regions) and are indicated by arrows. C Schematic representation o
Integrative Genomics Viewer (IGV) for patient II:1. The c.193C> T mutation in
the gene (arrow). D Sanger sequencing confirmed the homozygous mutat
in both parents (I:1 and I:2) and in II:2 (lower panel). II:3 was not a carrier.the institutional review board of the Ethics Committee
of the University Hospital of Cologne. It was performed
in adherence to the tenets of the declaration of Helsinki.
Written consent was obtained from all participants.
Venous blood samples were obtained for DNA extrac-
tion and genomic DNA was isolated following standard
protocols.
In both patients (II:1, female, 55 years) and II:4 (male,
53 years; Figure 1A), the diagnosis was established by
medical history and detailed evaluation of vision and
hearing. Ophthalmological examination consisted of fun-
duscopy, standard ERG, perimetry, measurement of dark
adaptation, Farnsworth D-15 color test and determin-
ation of visual acuity. II:1 underwent neurological exam-
ination after the identification of the homozygous
ABHD12 mutation.
Auditory function of both patients was assessed by pure
tone audiometry, speech-audiometry, and tympanometry.
Hearing impairment was classified as mild (20–40 dB),tigations. A Pedigree of the family described herein. B Graphical view
ing homozygosity by descent were identified on chromosomes 1 and
f the mapped sequencing reads (reverse strand) visualized with the
exon 2 of ABHD12 was present in all 87 reads covering this region of
ion in both patients (upper panel). It was found in heterozygous state
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(95 dB).Linkage analysis
Based on the parental consanguinity and the assumption
of autosomal recessive inheritance, we performed genome-
wide homozygosity mapping using the Affymetrix
GeneChip Human Mapping 10 k Array, version 2.0
(Affymetrix, Santa Clara, CA, USA). GRR [6] and
PedCheck [7] were used to verify relationships and to
identify Mendelian errors. Non-parametric linkage analysis
was carried out with MERLIN [8]. Parametric linkage and
haplotype analysis were performed using ALLEGRO [9]
assuming autosomal recessive inheritance, full penetrance
and a disease gene frequency of 0.0001. All data handling
was performed using the graphical user interface
ALOHOMORA [10]. Graphic output of haplotypes was
generated with HaploPainter [11].Sequence capture and next-generation sequencing
The coding exons of 378 genes located in the three
homozygosity-by-descent (HBD) regions (RefSeq data-
base) corresponded to 2855 regions and 505 kb of
sequence, respectively, and were targeted with a custo-
mized 385 k sequence capture array (Roche NimbleGen).
Genomic DNA from patient II:1 was fragmented (Covaris
S2 AFA system) and ligated to sequencing-specific
adaptors. Sample was enriched by array hybridization, fol-
lowed by elution and post-capture amplification by
ligation-mediated (LM-) PCR. This amplified DNA was
subjected to emulsion PCR (emPCR) and subsequent mas-
sively parallel sequencing on a Roche 454 GS FLX plat-
form. A total of 1,182,726 reads were generated
corresponding to nearly 400 Mb of sequence information.
Approximately 98% of the reads mapped to regions of the
hg19 genome, resulting in a 56-fold average depth of
coverage for all targeted regions. Less than 1% of the tar-
get regions were not covered by at least one unique read,
whereas 92% of the regions were covered more than 15-
fold. Sequence data for the ABHD12 gene were compared
to the reference sequences NM_001042472.2 and
NM_015600.4. The identified ABHD12 variant was vali-
dated by Sanger sequencing.Table 1 Homozygous SNVs without SNP annotation identified
Gene Refseq cds (ref./var.)
ABHD12 NM_001042472.2 NM_015600.4 c.193C> T
ID1 NM_002165 c.34 G>A
RGS7 NM_002924 c.200 T > C
NA, not annotated.Results
Clinical evaluation
By history, both affected siblings achieved normal psy-
chomotor development including acquisition of speech
and language. In both, hearing loss was first noted at the
age of 14 years (together with bilateral tinnitus after a
severe influenza infection in II:1), but probably occurred
earlier. The earliest audiology reports that were available
to us referred to investigations performed at the age of
17 years (patient II:1) and 24 years (patient II:4), respect-
ively, both showing moderate-to-severe bilateral neuro-
sensory hearing impairment. Both patients had normal
ear canals and tympanic membranes and experienced
progressive hearing loss, leading to severe (right) to pro-
found (left) hearing loss. Patient II:1 complained about
mild imbalance. A high-resolution CT of the temporal
bones and the brain in II:1 was normal. Both patients
used hearing aids in the past and received cochlear
implants around the age of 35 years.
Nyctalopia became apparent at the age of 18 years in
both patients. II:1 underwent sequential bilateral cataract
surgery at the age of 26 and 29 years, respectively. Best
visual acuity was 20/25 (6/9) bilaterally at the age of
30 years. Dark adaptation, color vision, and ERG were
moderately abnormal compared to her brother. Ten
years later, at the age of 40 years, funduscopy revealed
peripheral retinal changes with fine macular pigmentary
changes and best corrected visual acuity of 20/200 (6/
60). Last exam at the age of 55 years revealed best
corrected visual acuity of 20/400 (6/120) for the right
eye and counting fingers for the left eye, left esotropia,
20° of visual fields bilaterally, a cup-disc ratio of 0.9 bi-
laterally from glaucoma on topical therapy, and fine ret-
inal spicules at the equator.
For II:4, examination records were available from the age
of 23 years onward and gave similar results in both eyes.
Best corrected visual acuity was 20/100 (6/30) with early
posterior subcapsular cataract, vitreous degeneration,
marked pallor of optic disc, marked narrowing of retinal
vessels, and peripheral retinal pigmentation. Abnormal
dark adaptation, constricted visual fields, markedly reduced
ERG, and normal Farnsworth D-15 color test supported
the clinical diagnosis of USH. Eye exam at the age of
38 years revealed best corrected visual acuity of finger
counting at 2 m, moderate posterior subcapsular cataract,by next-generation sequencing of mapped HBD regions
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spicules in both eyes.
At the most recent examination at the age of 50 years,
vision was reduced to light perception on both eyes with
moderate posterior capsular cataract, and medically con-
trolled glaucoma. The macular region was atrophic with
severe optic atrophy.
II:1 underwent neurological evaluation at the age of
53 years because of a four year history of gait imbalance
and writing difficulties for three years. There was a
history of tremor since the age of 19 years. Her examin-
ation revealed an ataxic gait with poor tandem walking.
She had an action tremor with writing cramp and invol-
untary athetotic movements of her fingers. Her finger to
nose exam, muscle tone, and deep tendon reflexes were
normal with negative Babinski sign. Brain morphology
was normal in a CT of the brain.
In both patients, examination of cranial nerves III, IV,
and VI revealed normal eye movements without nystag-
mus (neither spontaneous nor gaze-induced). Slow pur-
suit was smooth and saccades were accurate. Trigeminal
sensation, corneal reflexes and facial function were
intact. In general, disease progression was similar in
both cases.
Linkage analysis and mutation analysis of positional
candidate genes
We obtained a maximum parametric LOD score of
2.05 for the three chromosomal regions that showed
homozygosity-by-descent (HBD) in II:1 and II:4, on
chromosomes 1q43-q44 (8.54 Mb), 20p13-p12.2 (10.48 Mb),
and 20p11.23-q12 (19.35 Mb) (Figure 1B). Direct sequencing
of all coding exons excluded mutations in the NINL gene on
chromosome 20p11.21, encoding ninein-like protein which
has been shown to interact with the USH protein complex
through usherin (USH2A) [12]. Although the causative mu-
tation most likely resides in the longest HBD segment [13],
we decided to analyze the coding exons contained in all can-
didate loci simultaneously.
Next-generation sequencing
276 high-confidence sequence variations were annotated
in the target regions (121 non-synonymous single nu-
cleotide variants (SNVs), 108 synonymous SNVs, 43
frameshift insertions/deletions and 4 in-frame-inser-
tions/deletions). Heterozygous variants, variants anno-
tated as single-nucleotide polymorphism in dbSNP135
and all synonymous variants were neglected. Question-
able changes in homopolymer stretches were assessed
through visualization with the Integrative Genomics
Viewer. Finally, three homozygous variants, including
one nonsense mutation, remained (Table 1). This non-
sense mutation (c.193C>T/p.Arg65X) is located in exon
2 of the ABHD12 gene (Figure 1C). It was confirmed bySanger sequencing (Figure 1D) and showed perfect cose-
gregation with the disease in the family. It is neither
present in the databases of the 1000genomes project
(http://www.1000genomes.org), which lists ABHD12
variants found in 1092 individuals from four different
populations, nor in the Exome Variant Server database
(http://evs.gs.washington.edu/EVS).
DISCUSSION
Recent studies indicate a population-prevalence for USH
of 1/6000 [14]. Children with USH initially have non-
syndromic hearing loss (NSHL): RP manifests in the first
(USH1) or second (USH2, USH3) decade of life. At least
10% of the hearing-impaired children carry mutations in
USH genes, making USH an important differential diag-
nosis. Molecular genetic testing can confirm or exclude
USH at an early time point, even before the onset of
visual problems, and may help limiting detailed ophthal-
mological follow-up in deaf children to those with USH-
causing mutations. Moreover, because certain mutations
in USH genes cause hearing impairment without retinal
degeneration, USH-causing mutations will be unevitably
identified in children with apparently NSHL by mas-
sively parallel NGS of all known deafness genes – an ap-
proach that will become a diagnostic routine within the
next few years.
Mutations in the known USH genes account for
72 – 86% of cases [15,16]. The remainder may be due to
mutations far outside the coding regions [17] or large
structural rearrangements [18] in these genes that escape
detection by genomic DNA amplification and sequen-
cing of the coding exons, and to further genetic hetero-
geneity. Moreover, USH may be mimicked by clinically
overlapping conditions, such as Alström syndrome, or
by the co-occurrence of non-syndromic deafness and RP
in the same individual [19]. Therefore, the awareness of
potential differential diagnoses is important when seek-
ing molecular verification of the clinical diagnosis.
Both patients from our family have deafness, RP and
cataracts, all symptoms compatible with USH. Linkage
analysis excluded all loci for known USH genes, and
targeted NGS revealed an ABHD12 nonsense mutation
segregating with disease in the family. Truncating
ABHD12 mutations have been shown to cause PHARC,
a neurodegenerative disease with polyneuropathy, hear-
ing loss, ataxia, RP, and early cataract [20]. II:1 therefore
underwent neurological examination which revealed
ataxia – a symptom that may be present in USH1 and
USH3 due to the affection of vestibular hair cells. Most
patients with PHARC and confirmed ABHD12 muta-
tions had ataxia, and these patients had cerebellar
atrophy or peripheral polyneuropathy or both [20].
There were no obvious signs of polyneuropathy in
patient II:1, and no indication of cerebellar atrophy in
Eisenberger et al. Orphanet Journal of Rare Diseases 2012, 7:59 Page 5 of 6
http://www.ojrd.com/content/7/1/59the cranial CT scan. However, her balance problems
could result from polyneuropathy that remained un-
detected because detailed investigation of the peripheral
nerves had been omitted as long as USH was the clinical
diagnosis. II:4 did not complain about balance problems,
indicating that ataxia was either very mild or not
present. Unfortunately, this patient was not available
anymore for detailed clinical follow-up. However, given
the homozygous ABHD12 nonsense mutation segregat-
ing with the disease, the phenotype in our family can be
considered a variant of PHARC.
In retinal photoreceptor cells, the USH protein inter-
actome presumably plays a role in transport, trafficking
and synaptic function; in the inner ear, the USH protein
interactions are important for hair cell development,
maintenance, and for tip link formation and hence
mechanotransduction [21-23]. The only known USH3
protein known, clarin-1, has recently been shown to be
part of this interactome as well [24]. The PHARC pro-
tein ABHD12 hydrolyzes 2-arachidonoyl glycerol, an
endocannabinoid lipid transmitter that acts on canna-
binoid receptors CB1 and CB2. The pathway affected in
PHARC is not yet known to be related to the USH pro-
tein complex. As can be expected because of the RP
component in PHARC, ABHD12 is expressed in the
retina [20], but no details are available on inner ear
expression. Further studies are needed to determine the
expression of ABHD12 on the cellular and subcellular
level in both sensory systems. The investigation of poten-
tial interactions of ABHD12 with the known USH proteins
will be crucial to find out if the clinical overlap of PHARC
and USH is based on a functional relationship between
these proteins.
Conclusions
We suggest that PHARC should be taken into account as
differential diagnosis for USH, especially in “USH3-like”
patients with progressive hearing loss and balance pro-
blems. Comprehensive genetic analysis, mainly by NGS-
based approaches, will increasingly be helpful in correcting
the diagnosis (reverse phenotyping) [25] and thereby im-
prove patient management.
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